People to be entitled to time off work if they lose baby before 24 weeks
Angela Rayner has said that the change will give 'people time away from work to grieve'. Under current rules, parents are entitled to up to two weeks of bereavement leave if a child dies before they turn 18, or they experience a stillbirth after 24 weeks of pregnancy.
Amendments to the Employment Rights Bill, will see the right to 'at least one week's leave' expanded to people who lose a pregnancy before 24 weeks. The exact length of the leave will be specified in later legislation after a consultation. The Bill already makes provision to expand bereavement leave, giving employees protected time off to grieve the loss of a loved one.
READ MORE: One of two boys found dead on railway line pictured
READ MORE: Highly infectious new Covid Stratus takes over UK with unique symptom
Business Secretary Jonathan Reynolds has said that the amendments will offer 'dignity and respect'. 'For many families, including mine, that have been affected by pregnancy loss, the decision around returning to work or taking sick leave to grieve properly can make an already painful experience even more difficult,' he said.
'Grief doesn't follow a timetable, and expanding rights to leave for pregnancy loss will ensure every family gets the time they need to heal without worrying about their job.' Deputy Prime Minister Ms Rayner similarly said that 'no-one who is going through the heartbreak of pregnancy loss should have to go back to work before they are ready'.
'I am proud that this Government is introducing a day-one right to protected time off work after experiencing pregnancy loss, giving people time away from work to grieve and spend time with their families,' she said. Vicki Robinson, chief executive of the Miscarriage Association, welcomed the announcement, saying it was 'a hugely important step that acknowledges the often very significant impact of pre-24-week loss, not only for those experiencing the physical loss, but for their partners too'.
It comes after ministers announced they would review the system of parental leave, declaring that the current system is 'not working' for families. Mr Reynolds said the Government will investigate the whole system for supporting new parents to take time off work when they have a baby, including maternity leave, paternity leave and shared arrangements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA's first marketing approval outside the U.S. ANKTIVA plus BCG offers a new option for eligible patients among the 16,400 to 18,000 people diagnosed with NMIBC in the UK each year1 CULVER CITY, Calif., July 08, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. This is the first marketing approval outside the U.S. for this novel lymphocyte-stimulating agent. "With the MHRA's authorization of ANKTIVA plus BCG, we can now offer our immunotherapy outside the U.S. to help patients with a disease that, if not effectively treated, can lead to bladder removal," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "This immune-boosting, lymphocyte-stimulating agent, the first of its kind, is central to our Cancer BioShield platform, which is designed to restore immune function and support long-term disease control." "ImmunityBio is honored to have received this important authorization from the UK MHRA. In light of the United States Most-Favored-Nation Prescription Drug Pricing policy implemented on May 12, 2025, we are actively evaluating our go-to-market strategy for the UK," said Richard Adcock, CEO and President of ImmunityBio. ANKTIVA is a first-in-class IL-15 agonist that activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells. It is designed to restore immune competence by reversing lymphopenia—a condition in which cancer and conventional therapies, such as chemotherapy, radiation and checkpoint inhibitors, reduce the number and function of immune cells. Restoring immune function is essential for immunosurveillance, immunogenic cell death, and sustained tumor control. The BioShield platform's effectiveness can be monitored using a routine complete blood count (CBC). ANKTIVA was designated a Breakthrough Therapy by the FDA and received approval from both the FDA and MHRA based on its safety and efficacy outcomes of complete response (CR) and duration of response (DOR). In a single-arm, multicenter trial, 77 evaluable patients received ANKTIVA with BCG for up to 37 months. As of the November 2023 data cutoff, the duration of complete response for some patients exceeded 47 months and remains ongoing. These extended duration of complete responses beyond 24 months with ANKTIVA and BCG surpasses the benchmark for meaningful clinical results set by experts from the International Bladder Cancer Group. ImmunityBio has also submitted regulatory applications to the European Medicines Agency (EMA) to expand availability of ANKTIVA across the 27 European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. About NMIBC CIS Bladder cancer is the 10th most commonly-diagnosed cancer globally,2 and in the UK, the Action Bladder Cancer UK estimates approximately 23,000 patients are diagnosed annually.1 At the time of diagnosis, about 80% of cases are non-muscle invasive bladder cancer (NMIBC), wherein the cancer is found only on the inner layer of the bladder wall.3 The standard therapy for NMIBC is intravesical instillation (delivery to the bladder via a catheter) of Bacillus Calmette-Guerin (BCG).4,5 BCG is a benign bacteria that induces an immune response in the bladder in proximity to the cancer cells, leading to clearance of the cancer in many patients. In ~30-40% of patients, however, BCG will fail, and in ~50% that initially respond, cancer will recur.6 About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit INDICATION AND IMPORTANT SAFETY INFORMATION FROM THE FDA LABEL INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patient with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. For more information about ANKTIVA, please see the Full Prescribing Information at You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482) About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. References: Action Bladder UK. Non-muscle invasive bladder cancer. May 2021. Available at: World Cancer Research Fund. Bladder Cancer Statistics. 2022. Available at: Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 4(1), 56–64. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. Grabe-Heyne, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023 Jun 2;13:1170124. doi: 10.3389/fonc.2023.1170124. Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. PMID: 37503461; PMCID: PMC10369196. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the belief that the MHRA authorization leads to increased revenue, the expectation that the EAP as previously reported will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, and the impact of the MHRA on the Company's ex-United States go to market strategy, including in light of the recently implemented United States Most Favored Nation pricing policy on the Company's go-to-market strategy in the United Kingdom, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding regulatory submissions in foreign jurisdictions, filing and review process and the timing thereof, (iii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iv) risks and uncertainties regarding commercial launch execution, success and timing, (v) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (vi) whether clinical trials will result in registrational pathways and the risks, (vii) whether clinical trial data will be accepted by regulatory agencies, (viii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (x) ImmunityBio's ability to retain and hire key personnel, (xi) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
£749 handout from DWP if you have any of these 87 muscle or joint problems
Personal Independence Payment (PIP) is a benefit designed for people who require extra help with everyday tasks due to an illness, disability or mental health condition. It is worth up to £749.80 every four weeks and is handed out by the Department for Work and Pensions ( DWP ). PIP is not an out of work benefit, so you may be eligible for PIP if you are working at present, reports MirrorOnline. READ MORE: Nationwide, Barclays and NatWest customers handed £185 to switch with rival bank Get breaking news on BirminghamLive WhatsApp, click the link to join How much you could get in PIP all depends on how your condition your health condition or disability impacts your life. There is no official list of conditions that make you eligible for PIP. As per DWP data, there are more than one million adults who are in receipt of PIP for musculoskeletal conditions, out of the 3.7million who claim PIP overall. Musculoskeletal conditions are injuries and disorders that impact the body's movement or musculoskeletal system such as muscles, tendons, ligaments, nerves, discs and blood vessels. PIP is made up of two components - a daily living rate and a mobility rate - and you can be entitled to both or just one of these. If you are eligible for both the enhanced rate of the daily living allowance and the mobility allowance, you would receive £749.80 a month. Daily Living Standard rate: £73.90 a week Enhanced rate: £110.40 a week Mobility Standard rate: £29.20 a week Enhanced rate: £77.05 a week Osteoarthritis Osteoarthritis of Hip Osteoarthritis of Knee Osteoarthritis of other single joint Primary generalised Osteoarthritis Chronic pain syndrome Chronic fatigue syndrome (CFS) Fibromyalgia Pain syndromes - Chronic - Other / type not known Inflammatory arthritis Ankylosing spondylitis Arthritis - Psoriatic Arthritis - Reactive Inflammatory arthritis - Other / type not known Juvenile chronic arthritis (Still's disease) Rheumatoid arthritis Crystal deposition disorders Crystal deposition disorders - Other / type not known Gout Pseudogout Osteonecrosis and osteochondritis Osteochondritis Osteonecrosis Metabolic and endocrine disorders Osteomalacia Osteoporosis Other metabolic and endocrine disorders of musculoskeletal system Paget's disease Rickets Genetic disorders, dysplasias and malformations Achondroplasia Epiphyseal dysplasia - multiple Genetic disorders, dysplasias and malformations - Other / type not known Hereditary multiple exostosis (diaphyseal aclasis) Hypermobility syndrome Marfan's syndrome Osteogenesis imperfecta Benign tumours of bone Tumours of bone - benign Fracture complications Compartment syndrome (Volkmann's ischaemia) Fracture complications - Other / type not known Sudek's atrophy Other generalised musculoskeletal conditions Generalised musculoskeletal disease - Other / type not known Shoulder disorders Adhesive capsulitis (frozen shoulder) Rotator cuff disorder Shoulder disorders - Other / type not known Shoulder instability Elbow disorders Elbow disorders - Other / type not known Golfers elbow (medial epicondylitis) Tennis elbow (lateral epicondylitis) Wrist and hand disorders Carpal tunnel syndrome Dupuytren's contracture Tendon lesions Tenosynovitis Wrist and hand disorders - Other / type not known Neck disorders Cervical disc lesion Cervical spondylosis Neck disorders - Other / type not known Whiplash injury Non specific back pain Back pain - Non specific (mechanical) Specific back pain Back pain - Specific - Other / type not known Kyphosis Lumbar disc lesion Lumbar spondylosis (OA spine) Schuermann's disease Scoliosis Spinal stenosis Spondylolisthesis Hip disorders Dislocation of the hip - congenital Hip disorders - Other / type not known Perthes disease Slipped upper femoral epiphysis Knee disorders Bursitis Chondromalacia patellae Knee disorders - Other / type not known Ligamentous instability of knee Meniscal lesions Osgood schlatters disease Osteochondritis dissecans Patellar dislocation - Recurrent Ankle and foot disorders Ankle and foot disorders - Other / type not known Club foot (talipes) Fore foot pain (Metatarsalgia) Hallux valgus /rigidus Amputations Amputation - Lower limb(s) Amputation - Upper limb(s) Amputations - Upper & Lower limb/s Injuries/fracture/Dislocation Abdomen - Injuries/Fracture/Dislocation of Lower limb - Injuries/Fracture/Dislocation of Multiple - Injuries/Fracture/Dislocation Pelvis - Injuries/Fracture/Dislocation of Spine - Injuries/Fracture/Dislocation of Thorax - Injury/Fracture/Dislocation of Upper limb - Injury/Fracture/Dislocation of Other regional musculoskeletal disease Musculoskeletal disease - Regional / Localised - Other / type not known
Yahoo
2 hours ago
- Yahoo
Post Office scandal victims place hope in inquiry report
Scottish victims of the Post Office Horizon scandal say they hope the first part of the public inquiry's final report will bring justice a step closer. Volume one, which will focus on the human impact and compensation, will be published at midday on Tuesday. More than 70 people in Scotland have had their convictions overturned after they were wrongly accused of crimes like theft because of the faulty Post Office IT system. But the scandal runs deeper than those prosecuted, with many more people losing livelihoods and relationships as a result of false accusations. Thousands of people across the UK have been affected by what has been described as the most widespread miscarriage of justice of recent times. A statutory public inquiry into the UK-wide scandal was established in 2021 and has heard from hundreds of witnesses from across the country. Victims, lawyers and journalists will be among those gathering in central London when the chair of the inquiry - Sir Wyn Williams - delivers the first part of his report. Keith Macaldowie gave evidence to the inquiry when it came to Glasgow in 2022. He ran a post office in Greenock and was forced to resign in 2011 after an alleged shortfall of £10,000 was uncovered. He was not convicted but lost his livelihood and told the inquiry he came close to suicide. He finally reached a financial settlement with the company in March this year. Speaking ahead of the publication of the findings, he said: "What I hope from the first part of the inquiry report is for the redress scheme to speed up and get everyone paid what they are due. "I also hope that it helps with the police investigation that is ongoing." Ravinder Naga falsely confessed to stealing money from his mother's post office in Greenock in 2009 to protect her from going to prison. Appeal judges overturned his conviction last year. He told BBC Scotland News he wants accountability. "The people who died, they don't know their names have been cleared. They died before all this came out," he said. While the focus of Tuesday's report will be on the victims and compensation, Mr Naga said he ultimately wants those responsible for the scandal to go to prison. "I want justice," he added. Solicitor Advocate Stuart Munro is head of specialist litigation at Livingstone Brown and has been representing one of the first Scottish victims to have her conviction quashed. He said the Post Office Horizon scandal was one of the most far-reaching miscarriages of justice in British history. "Countless lives were ruined. Its victims will now be looking to Sir Wyn Williams to lay bare the truth of what happened and to recommend measures to ensure nothing like this can ever happen again. "That process begins on Tuesday with the publication of the first part of this final report." 'Post Office compensation wait is taking its toll' Sub-postmasters wrongly told to pay back money Post Office Horizon scandal: Why hundreds were wrongly prosecuted What are the different Post Office compensation schemes?
